International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 662, P. 124540 - 124540
Published: July 27, 2024
Language: Английский
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 763 - 772
Published: May 17, 2024
Language: Английский
Citations
19
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 381, P. 113559 - 113559
Published: Feb. 27, 2025
Language: Английский
Citations
1
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(5), P. 550 - 550
Published: April 23, 2025
Advanced biotherapeutic systems such as gene therapy, mRNA lipid nanoparticles, antibody–drug conjugates, fusion proteins, and cell therapy have proven to be promising platforms for delivering targeted biologic therapeutics. Preserving the intrinsic stability of these advanced therapeutics is essential maintain their innate structure, functionality, shelf life. Nevertheless, various challenges obstacles arise during formulation development throughout storage period due complex nature sensitivity stress factors. Key concerns include physical degradation chemical instability factors fluctuations in pH temperature, which results conformational colloidal instabilities biologics, adversely affecting quality therapeutic efficacy. This review emphasizes key issues associated with approaches identify overcome them. In brittleness viral vectors encapsulation limits stability, requiring use stabilizers, excipients, lyophilization. Keeping cells viable whole process, from culture final formulation, still a major difficulty. therapeutics, stabilization strategies optimization nucleotides compositions are used address both nanoparticles. Monoclonal antibodies colloidally conformationally unstable. Hence, buffers stabilizers useful stability. Although proteins monoclonal share structural similarities, they show similar pattern instability. Antibody–drug conjugates possess conjugation linker outlines biotherapeutics provides insights into challenges.
Language: Английский
Citations
1
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 30, 2025
Abstract Intranasal delivery of mRNA vaccines offers promising opportunities to combat airborne viruses like SARS‐CoV‐2 by provoking mucosal immunity, which not only defends against respiratory infection but also prevents contagious transmission. However, the development nasal has been hampered lack effective means overcome mucus barrier. Herein, ionizable lipid‐incorporated liquid lipid nanoparticles (iLLNs) capable delivering cargo across airway mucosa are designed. Adjusting ratios and cationic lipids allows fine‐tuning p K a iLLNs range pH (5.5–6.5), thus facilitating penetration via formation near‐neutral, PEGylated muco‐inert surfaces. When nasally administered mice, top candidate iLLN‐2/mRNA complexes enable about 60‐fold greater reporter gene expression in cavity, compared benchmark mRNA‐lipid (ALC‐LNP) having same composition as that BNT162b2 vaccine. Moreover, prime‐boost intranasal immunization elicits magnitude spike‐specific IgA IgG response than ALC‐LNP, without triggering any noticeable inflammatory reactions. Taken together, these results provide useful insights for design deliverable formulations prophylactic applications.
Language: Английский
Citations
0
Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106792 - 106792
Published: March 1, 2025
Language: Английский
Citations
0
Bioengineering, Journal Year: 2025, Volume and Issue: 12(4), P. 362 - 362
Published: March 31, 2025
Active targeting nanoparticles are a new generation of drug and gene delivery systems with the potential for greatly improved therapeutics compared to conventional nanomedicine approaches. Despite their potential, translation active faces challenges in production scale-up batch consistency. Accurate quality control methods nanoparticle therapeutic payload coating characterization critical attaining desired levels repeatability, drug/gene loading efficiency, molecule effectiveness, safety profiles. Current limitations technologies, such as relying on ensemble-average analysis, pose assessing content surface modification heterogeneity, which can affect outcomes. Single-molecule analysis technologies have emerged promising alternative, offering rich information heterogeneity stochastic variations between batches. This review first evaluates identifies traditional tools that rely indirect, bulk solution quantification methods. Subsequently, newly emerging introduced targeted moiety efficiencies single-nanoparticle resolution, help guide researchers towards advancing into clinical setting.
Language: Английский
Citations
0
Biomacromolecules, Journal Year: 2025, Volume and Issue: unknown
Published: May 10, 2025
Since the remarkable breakthrough of COVID-19 mRNA vaccines, lipid nanoparticles (LNPs) have gained substantial attention as most cutting-edge clinical formulations for delivery. PEGylated (PEG-lipid) has been regarded an essential constituent LNPs that helps to prolong their systemic circulation by preventing particle aggregation in blood and sequestration mononuclear phagocyte system. Herein, we synthesized a series mRNA-loaded replacing ALC-0159 (a PEG-lipid used Comirnaty formulation) with amphiphilic PEG-polycarbonate diblock copolymers (PC-HNPs). Interestingly, variations polycarbonate block length structure significantly influenced encapsulation efficiency, transfection potency, colloidal stability, PEG shedding rate PC-HNPs. In vivo ex bioluminescence imaging revealed upon subcutaneous administration mice, leading candidate PC3-HNP achieved lymph node accumulation comparable conventional ALC-0159-based LNP formulation while avoiding undesirable liver accumulation. Our findings may provide valuable information construction next-generation nanocarriers effective
Language: Английский
Citations
0
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 662, P. 124540 - 124540
Published: July 27, 2024
Language: Английский
Citations
1